EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome

Objectives To develop a score for assessment of patients' symptoms in primary Sjögren's syndrome (SS): the EULAR SS Patient Reported Index (ESSPRI). Methods Dryness, pain, somatic and mental fatigue were identified as the main symptoms of patients with primary SS, in studies developing the Profile of Fatigue and Discomfort (PROFAD) and Sicca Symptoms Inventory (SSI). It was suspected that a single 0–10 numerical scale for each domain was sufficient to assess these symptoms. These four scales were gathered to form the ESSPRI. 230 patients, from 12 countries completed the ESSPRI, SSI and PROFAD questionnaires and a 0–10 patient global assessment (PGA). Correlations between each symptom and PGA were obtained. Multiple regression modelling, using PGA as ‘gold standard’ was used to select domains and estimate their weights. Results PGA had good correlation with dryness, limb pain, fatigue and mental fatigue (r=0.49–0.59, all p<0.0001), but correlated less well with individual dryness features. In multivariate analysis, dryness, limb pain and fatigue, but not mental fatigue, were significantly associated with PGA; weights derived from the regression were identical for these three domains. Thus, ESSPRI was redefined as the mean of the three scales: dryness, limb pain and fatigue. Lastly, ESSPRI significantly correlated with PGA (r=0.70), PROFAD (r=0.73) and SSI (r=0.66). Conclusion ESSPRI is a very simple index designed to measure patients' symptoms in primary SS. It has good construct validity and is well correlated with SSI and PROFAD. ESSPRI should now be validated for use as an outcome measure in clinical trials.

[1]  A. Vissink,et al.  Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. , 2010, Arthritis and rheumatism.

[2]  G. Baron,et al.  EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome , 2009, Annals of the rheumatic diseases.

[3]  R. Barry,et al.  Patient-reported outcomes in primary Sjogren's syndrome: comparison of the long and short versions of the Profile of Fatigue and Discomfort--Sicca Symptoms Inventory. , 2008, Rheumatology.

[4]  R. Barry,et al.  The Sjögren's Syndrome Damage Index--a damage index for use in clinical trials and observational studies in primary Sjögren's syndrome. , 2008, Rheumatology.

[5]  D A Isenberg,et al.  Sjögren's Systemic Clinical Activity Index (SCAI)--a systemic disease activity measure for use in clinical trials in primary Sjögren's syndrome. , 2007, Rheumatology.

[6]  S. Bombardieri,et al.  Sjögren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients. , 2007, Arthritis and rheumatism.

[7]  A. Vissink,et al.  Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. , 2005, Arthritis and rheumatism.

[8]  S. Bowman,et al.  Measurement of fatigue and discomfort in primary Sjogren's syndrome using a new questionnaire tool. , 2004, Rheumatology.

[9]  S. Bowman,et al.  Validation of the Sicca Symptoms Inventory for clinical studies of Sjögren's syndrome. , 2003, The Journal of rheumatology.

[10]  R. Jonsson,et al.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group , 2002, Annals of the rheumatic diseases.

[11]  Stanley B. Cohen,et al.  A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. , 2002, Arthritis and rheumatism.

[12]  R. Jonsson,et al.  Revisiting Sjögren's syndrome in the new millennium: perspectives on assessment and outcome measures. Report of a workshop held on 23 March 2000 at Oxford, UK. , 2001, Rheumatology.

[13]  S. Bowman,et al.  Outcome measures in Sjögren's syndrome. , 2001, Rheumatology.

[14]  P. Fox,et al.  Clinical course of primary Sjögren's syndrome: salivary, oral, and serologic aspects. , 2000, The Journal of rheumatology.

[15]  I. Griffiths,et al.  Primary Sjögren's syndrome in the North East of England: a long-term follow-up study. , 1999, Rheumatology.

[16]  F. Vivino,et al.  Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. , 1999, Archives of internal medicine.

[17]  A. Silman,et al.  Weak association between subjective symptoms of and objective testing for dry eyes and dry mouth: results from a population based study , 1998, Annals of the rheumatic diseases.

[18]  A. Vissink,et al.  Rituximab treatment in primary Sjogren's syndrome , 2005 .

[19]  S. Pillemer,et al.  Outcome measures for Sjögren's syndrome, April 10-11, 2003, Bethesda, Maryland, USA. , 2005, The Journal of rheumatology.

[20]  R. Jonsson,et al.  Current concepts on diagnosis, autoantibodies and therapy in Sjögren's syndrome. , 2000, Scandinavian journal of rheumatology.

[21]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.